bpc-157 human randomized controlled trials as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Christopher Mendias, PhD, gets four

Martinez-Nunez and colleagues say the data revealed novel compounds that could inhibit SARS-CoV-2 replication, based on the QUBO model and the more traditional Tanimoto fingerprint

Kisspeptin-10 Strength: 10 mg Expanded-strength option for patients discussing a more advanced provider-guided sexual wellness protocol

304, L112L124

A phase 2 randomised controlled trial published in the New England Journal of Medicine (2023) reported substantial weight loss and improvements in glycaemic parameters, though the trial was conducted in a closely monitored clinical setting with defined eligibility criteria

Michael Irizarry, Eisais senior vice president of clinical research in neurology

doi: 10.1152/ajpgi.00494.2010